Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer

• Main Authors: Edoardo Mortato (Author), Anna Paola De Caro (Author), Luca Schinzari (Author), Sonia Maniglio (Author), Carmelo Laface (Author), Gerardo Cazzato (Author), Caterina Foti (Author), Francesca Ambrogio (Author)
• Format: Book
• Published: PAGEPress Publications, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Despite their efficacy,...